TP53 and acute myeloid leukemia: We focused on TP53-mutant AML/MDS because current therapeutic approaches, i.e., intensive induction chemotherapy or HMAs+/− Ven have failed to improve patient outcomes (Pollyea et al, 2022), and thus, immunotherapeutic strategies are currently being tested in this clinically challenging patient cohort (Sallman et al, 2022).